Pancreas transplantation utilizing thymoglobulin, sirolimus, and cyclosporine

Transplantation

Volumn 81, Issue 8, 2006, Pages 1101-1105

  Knight, Richard J ^a   Kerman, Ronald H ^a   Zela, Scott ^a   Podbielski, Jeannette ^a   Podder, Hemangshu ^a   Van Buren, Charles T ^a   Katz, Stephen ^a   Kahan, Barry D ^a  

^a UNIVERSITY OF TEXAS MEDICAL SCHOOL   (United States)

Author keywords

Immune monitoring; Immunosuppression; Pancreas transplantation

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CEFAZOLIN; COTRIMOXAZOLE; CYCLOSPORIN; CYCLOSPORIN A; GANCICLOVIR; HLA ANTIBODY; HLA ANTIGEN CLASS 2; METHYLPREDNISOLONE; RAPAMYCIN; THYMOCYTE ANTIBODY;

ADULT; ARTHRALGIA; ARTICLE; CELL COUNT; CLINICAL ARTICLE; CLINICAL PROTOCOL; FEMALE; FLOW CYTOMETRY; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOREGULATION; LEUKOPENIA; MALE; PANCREAS; PANCREAS TRANSPLANTATION; PNEUMONIA; PRIORITY JOURNAL; SUPPRESSOR CELL; T LYMPHOCYTE SUBPOPULATION; THROMBOCYTOPENIA;

ADULT; ANTILYMPHOCYTE SERUM; CYCLOSPORINE; CYTOMEGALOVIRUS INFECTIONS; FEMALE; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOANTIBODIES; MALE; MIDDLE AGED; PANCREAS TRANSPLANTATION; PROSPECTIVE STUDIES; SIROLIMUS; T-LYMPHOCYTE SUBSETS;

EID: 33646816002     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.tp.0000203800.90554.07     Document Type: Article

References (20)

1. Burke GR, Kaufman D, Millis J, et al. Prospective, randomized trial of the effect of antibody induction in simultaneous pancreas and kidney transplantation: three-year results. Transplantation 2004; 77(8): 1269.
2. Kaufman DB, Leventhal IR, Koffron AJ, et al. A prospective study of rapid corticosteroid elimination in simultaneous pancreas-kidney transplantation. Transplantation 2002; 73(2): 169.
3. Stratta R, Alloway R, Lo A, Hodge E. Two-dose daclizumab regimen in simultaneous kidney-pancreas transplant recipients: primary endpoint analysis of a multicenter, randomized study. Transplantation 2003; 75(8): 1260.
4. Gruessner AC, Sutherland DE. Pancreas transplant outcomes for United States (US) and Non-US cases as reported to the United Network for Organ Sharing (UNOS) and the International Pancreas Transplant Registry (IOPTR) as of May 2003. Los Angeles: UCLA Tissue Typing Laboratory, 2004.
5. Knight RJ, Kerman R, Zela S, et al. Thymoglobulin, sirolimus and reduced dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation. Transplantation 2003; 75: 1301.
6. Terasaki PI, Ozawa M. Predicting kidney graft failure by HLA Antibodies: a prospective trial. Am J Transplant 2004; 4: 438.
7. Worthington J, Martin S, Al-Husseini D, et al. Posttransplantation production of donor HLA-specific antibodies as a predictor of renal transplant outcome. Transplantation 2003; 75(7): 1034.
8. Kowalski R, Post D, Schneider M, et al. Immune cell function testing: an adjunct to therapeutic drug monitoring in transplant patient management. Clin Transplant 2003; 17(2): 77.
9. Kerman R, Buren CV, Payne W, et al. The influence of pretransplant blood transfusions from random donors on immune parameters affecting cadaveric allograft survival. Transplantation 1983; 36: 50.
10. Kerman RH, Suskind B, Buys I, et al. Flow cytometry-detected IgG is not a contraindication to renal allotransplantation: IgM may be beneficial to outcome. Transplantation 1999; 68: 1855.
11. Agostino G, Kahan BD, Kerman RH. Suppression of mixed lymphocyte culture using leukocytes from normal individuals, uremic individuals and allograft recipients. Transplantation 1982; 34(6): 367.
12. Knight RJ, Kerman RH, Schoenberg L, et al. The selective use of basiliximab versus thymoglobulin in combination with sirolimus for cadaveric renal transplant recipients at low versus high risk for delayed graft function. Transplantation 2004; 78: 904.
13. Khwaja K, Asolati M, Harmon I, et al. Outcome at 3 years with a prednisone-free maintenance regimen: a single-center experience with 349 kidney transplant recipients. Am J Transplant 2004; 4: 980.
14. Freise C, Kang S, Feng S, et al. Experience with steroid-free maintenance immunosuppression in simultaneous pancreas-kidney transplantation. Transplant Proceedings 2004; 36(4): 1067.
15. Cianacio G, Burke G, Gaynor J, et al. A randomized long-term trial of tacrolimus/sirolimus versus tacrolimus/mycophenolate mofetil versus cyclosporine (neoral)/sirolimus in renal transplantation. II. Survival, function, and protocol compliance at 1 year. Transplantation 2004; 77(2): 252.
16. Lilliu H, Brun-Strang C, Pen CL, et al. Cost-minimization study comparing Simulect vs. Thymoglobulin in renal transplant induction. Clin Transplant 2004; 18(3): 247.
17. Ozaki K, Camara N, Galante N, et al. Decreased cytomegalovirus intection after antilymphocyte therapy in sirolimus-treated renal transplant patients. Int Immunopharmacol 2005; 5(1): 103.
18. Trotter J, Wallack A, Steinberg T. Low incidence of cytomegalovirus disease in liver transplant recipients receiving sirolimus primary immunosuppression with 3-day corticosteroid taper. Transplant Infectious Disease 2003; 5(4): 174.
19. Kahan B, Knight R, Schoenberg L, et al. Ten years of sirolimus therapy for human renal transplantation: The University of Texas at Houston experience. Transplant Proceedings 2003; 35 (Suppl3A): 25S.
20. Agha I, Rueda J, Alvarez A, et al. Short course induction immunosuppression with thymoglobulin for renal transplant recipients. Transplantation 2002; 73: 473.